Ramin Yaghobi

Dr. Ramin Yaghobi


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SSSaeede Soleimanian
Saeede Soleimanian
RYRamin Yaghobi
Ramin Yaghobi
The worldwide struggle against the coronavirus disease 2019 (COVID-19) as a public health crisis continues to sweep across the globe. Up to now, effective antiviral treatment against COVID-19 is not available. Therefore, throughout virus infections, a thorough clarification of the virus-host immune system interactions will be most probably helpful to encounter these challenges. Emerging evidence suggests that just like SARS and MERS, COVID-19 primarily suppresses the innate immune system, enabling its stable propagation during the early stage of infection. Consequently, proinflammatory cytokines and chemokines have been increasing during infection progression associated with severe lung pathology. It is imperative to consider hyper inflammation in vaccine designing, as vaccine-induced immune responses must have a protective role against infection without leading to immunopathology. Among the front-line responders to viral infections, Natural Killer (NK) cells have immense therapeutic potential, forming a bridge between innate and adaptive responses. A subset of NK cells exhibits putatively increased effector functions against viruses following pathogen-specific and immunization. Memory NK cells have higher cytotoxicity and effector activity, compared with the conventional NK cells. As a pioneering strategy, prompt accumulation and long‐term maintenance of these memory NK cells could be an efficacious viral treatment. According to the high prevalence of human cytomegalovirus (HCMV) infection in the world, it remains to be determined whether HCMV adaptive NK cells could play a protective role against this new emerging virus. In addition, the new adaptive-like KIR+NKG2C+ NK cell subset (the adaptive-like lung tissue residue [tr]NK cell) in the context of the respiratory infection at this site could specifically exhibit the expansion upon COVID-19. Another aspect of NK cells we should note, utilizing modified NK cells such as allogeneic off-the-shelf CAR-NK cells as a state-of-the-art strategy for the treatment of COVID-19. In this line, we speculate introducing NKG2C into chimeric antigen receptors in NK cells might be a potential approach in future viral immunotherapy for emerging viruses. In this contribution, we will briefly discuss the current status and future perspective of NK cells, which provide to successfully exploit NK cell-mediated antiviral activity that may offer important new tools in COVID-19 treatment.

1 September 2009 in Transplantation Proceedings
Verified
Journal Article
Closed access
RYRamin Yaghobi
Ramin Yaghobi
MRM. Ramzi
M. Ramzi
SDS. Dehghani
S. Dehghani

28 January 2019 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
ZFZhaleh Farokhizadeh
Zhaleh Farokhizadeh
SDSahar Dehbidi
Sahar Dehbidi
BGBita Geramizadeh
Bita Geramizadeh
RYRamin Yaghobi
Ramin Yaghobi
SMSeyed Ali Malekhosseini
Seyed Ali Malekhosseini
MKMohammad Hossein Karimi
Mohammad Hossein Karimi
Farokhizadeh Z, et al. Ann Lab Med. 2019 Jan;39(1):58-66. https://doi.org/10.3343/alm.2019.39.1.58

22 September 2013 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
MSMahdiyar Iravani Saadi
Mahdiyar Iravani Saadi
RYRamin Yaghobi
Ramin Yaghobi
MKMohammad Hossein Karimi
Mohammad Hossein Karimi
BGBita Geramizadeh
Bita Geramizadeh
MRMani Ramzi
Mani Ramzi
MZMaryam Zakerinia
Maryam Zakerinia

1 June 2013 in Viral Immunology
Verified
Journal Article
Closed access
SHSara Hejr
Sara Hejr
MKMohammad Hossein Karimi
Mohammad Hossein Karimi
RYRamin Yaghobi
Ramin Yaghobi
EKEskandar Kamali-Sarvestani
Eskandar Kamali-Sarvestani
BGBita Geramizadeh
Bita Geramizadeh
JRJamshid Roozbeh
Jamshid Roozbeh
Inflammatory cytokine gene polymorphisms may influence the hepatic and extrahepatic HBV-related disease in transplant patients. In this study, the association between IL-17, IL-23R, and IL-21 gene polymorphisms with hepatitis B virus (HBV) infection was evaluated in kidney transplant patients. In total, 220 kidney transplant patients were enrolled in this cross-sectional study between years 2007 and 2011. The genomic HBV DNA was identified using an HBV PCR detection Kit according to the manufacturer's instruction. The cytokine gene polymorphisms, including IL-17 197 A/G (rs2275913), IL-21 +1472 G/T (rs2055979), IL-21 5250 C/T (rs4833837), and IL-23R C/A (rs10889677) were evaluated by PCR-RFLP and ARMS-PCR protocols. The serum levels of IL-17 and IL-21 were analyzed in HBV infected and noninfected transplant patients by ELISA methods according to manufacturer's instructions. 70 of 220 (35%) transplant patients experienced acute rejection. HBV DNA was detected in 52 of 220 (23.64%) transplant patients. 16 of 52 (30.8%) HBV-infected kidney transplant patients experienced acute rejection. A significant higher frequency of C allele of IL-23R (rs10889677) polymorphism, a higher frequency of AG heterozygote genotype and A allele of IL-17-G197A (rs2275913) polymorphism, a higher frequency of TT homozygote genotype and T allele of IL-21-G1472T (rs2055979) polymorphism, and a higher frequency of CC homozygote genotype and C allele of IL-21-C5250T (rs4833837) polymorphism were found in HBV-infected kidney transplant patients with acute rejection. Diagnosis of the higher frequency of the IL-17, IL-21, and IL-23R cytokine genotypes and allele polymorphisms in HBV-infected kidney transplant patients who experienced acute rejection, illustrates the importance of Th17-related cytokine genetic patterns. A better evaluation of HBV infection in kidney transplant patients is needed.

1 April 2019 in Microbial Pathogenesis
Verified
Journal Article
Closed access
NZNeda Zareei
Neda Zareei
HMHamid Reza Miri
Hamid Reza Miri
MKMohammad Hossein Karimi
Mohammad Hossein Karimi
AAAfsoon Afshari
Afsoon Afshari
BGBita Geramizadeh
Bita Geramizadeh
RYRamin Yaghobi
Ramin Yaghobi